EyePoint Doses First Patients in Pivotal Phase 3 Trials for DURAVYU™ in Diabetic Macular Edema
EYPT has more than doubled off its 52-week low of $3.91 on elevated volume (2.1× avg).
Summary
EyePoint, Inc. announced the dosing of the first patients in its two global Phase 3 clinical trials (COMO and CAPRI) for DURAVYU™ in diabetic macular edema (DME), marking a significant advancement in its lead product candidate's development.
Key Events · Product Development and Regulatory · EYPT
-
Phase 3 DME Trials Initiated
EyePoint announced the dosing of the first patients in its global Phase 3 COMO and CAPRI clinical trials for DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME).
-
DURAVYU's Differentiated Profile
DURAVYU is highlighted as the only tyrosine kinase inhibitor (TKI) in Phase 3 for DME, offering a novel multi-mechanism of action and sustained delivery for at least six months.
-
Regulatory Alignment
The Phase 3 program design, informed by positive Phase 2 results, has alignment with both the U.S. FDA and European Medicines Agency (EMA), following an established non-inferiority regulatory pathway.
-
Anticipated Data Timeline
Topline data from the DME pivotal program is expected in the second half of 2027.
Analysis · EYPT · Industrial Applications And Services
This 8-K reports a critical milestone for EyePoint, Inc. as it initiates Phase 3 clinical trials for DURAVYU™ in diabetic macular edema (DME), a multi-billion dollar market. The company highlights DURAVYU's novel multi-mechanism of action and sustained-release delivery, positioning it as a potentially differentiated treatment. The trial design, aligned with FDA and EMA, aims for non-inferiority against standard of care, de-risking the regulatory pathway. This progress, alongside ongoing Phase 3 trials for wet AMD and a strong cash position into Q4 2027 (as previously reported), underscores the company's advancement in its pipeline and commitment to addressing serious retinal diseases. Investors should monitor the progress of these trials, with topline data for DME anticipated in 2H 2027.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.5% of the 1531 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EYPT was trading at $17.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $3.91 to $19.11. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.